Ano:
Autor:
Título:
Palavra-chave:

Endoscopy. 2020 Mar;52(3):E96-E97	Artigo on-line
Traction-assisted endoscopic submucosal dissection for a gastric lesion involving the pyloric ring and duodenal bulb Rodríguez-Carrasco M, Nunes G, Libânio D, Pimentel-Nunes P, Dinis-Ribeiro M
Clin Gastroenterol Hepatol. 2020 Jan 31. pii: S1542-3565(20)30111-7	Artigo on-line
Do Neutrophils Contribute to Development of Crohn's Disease and Ulcerative Colitis? Magro F, Estevinho MM
Int J Colorectal Dis. 2020 Jan;35(1):165-167	Ver Resumo  |   Artigo on-line
Endoscopic treatment of a foreign body-associated colonic perforation Morais R, Marques M, Macedo G
J Viral Hepat. 2020 Jan 18. doi: 10.1111/jvh.13261	Ver Resumo  |   Artigo on-line
Long-term safety and efficacy results in hepatitis C virus genotype 1-infected patients receiving ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in the TOPAZ-I and TOPAZ-II trials. Poordad F, Castro RE, Asatryan A, Aguilar H, Cacoub P, Dieterich D, Marinho RT, Carvalho A, Siddique A, Hu YB, Charafeddine M, Bondin M, Khan N, Cohen DE, Felizarta F The 3-DAA regimen consisting of ombitasvir/paritaprevir/ritonavir plus dasabuvir (OBV/PTV/r + DSV) ± ribavirin (RBV) has shown high sustained virologic response rates (~95%) in phase 3 clinical trials including >2300 HCV genotype 1-infected patients. Real-world evidence studies have confirmed the effectiveness of OBV/PTV/r ± DSV ± RBV in patients with chronic HCV genotype 1 infection and are consistent with clinical trial results. TOPAZ-I and TOPAZ-II are ongoing phase 3b trials, assessing safety, efficacy and long-term progression of liver disease and clinical outcomes for up to 5 years post-treatment in patients treated with OBV/PTV/r + DSV ± RBV. High rates of sustained virologic response (SVR) were achieved regardless of presence or absence of cirrhosis.In this report, we assessed the long-term progression of liver disease and incidence of clinical outcomes up to 3 years of post-treatment follow-up in patients with chronic HCV GT1 infection who were treated with (OBV/PTV/r + DSV) ± RBV in the TOPAZ-I and TOPAZ-II studies. Improvements were observed in liver disease markers including FIB-4, METAVIR and Child-Pugh scores as well as platelet counts. Clinical outcomes related to long-term progression of liver disease such as liver decompensation were infrequent (<1%). Hepatocellular carcinoma (HCC) occurred in 1.4% of cirrhotic patients
J Clin Med. 2020 Jan 2;9(1). pii: E125. doi: 10.3390/jcm9010125	Ver Resumo  |   Artigo on-line
Effectiveness of Two Dietary Approaches on the Quality of Life and Gastrointestinal Symptoms of Individuals with Irritable Bowel Syndrome Guerreiro MM, Santos Z, Carolino E, Correa J, Cravo M, Augusto F, Chagas C, Guerreiro CS
2138 artigos encontrados.  Pag 3 de 428